Albireo to Participate in Guggenheim Nantucket Therapeutics Conference
20 September 2022 - 2:00PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company
developing novel bile acid modulators to treat pediatric and adult
liver diseases, today announced participation in the Guggenheim
Therapeutics Conference in Nantucket, MA, from September 27-29,
2022. Ron Cooper, President and Chief Executive Officer of Albireo,
will be presenting on September 28, 2022, at 8:30 AM ET.
A replay of the webcast will be available on-demand on the
Albireo Investors page: ir.albireopharma.com.
About Albireo
Albireo Pharma is a rare disease company focused
on the development of novel bile acid modulators to treat pediatric
and adult liver diseases. Albireo’s lead product, Bylvay, was
approved by the U.S. FDA as the first drug for the treatment of
pruritus in all types of progressive familial intrahepatic
cholestasis (PFIC), and it is also being developed to treat other
rare pediatric cholestatic liver diseases with Phase 3 trials in
Alagille syndrome (ALGS) and biliary atresia, as well as Open-label
Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay is
reimbursed for the treatment of PFIC in Germany, England, Wales
& Northern Ireland, Scotland, Italy, and Belgium. The Company
has also completed a Phase 1 clinical trial for A3907 to advance
development in adult cholestatic liver disease, with IND-enabling
studies progressing with A2342 for viral and cholestatic liver
disease. Albireo was spun out from AstraZeneca in 2008 and is
headquartered in Boston, Massachusetts, with its key operating
subsidiary in Gothenburg, Sweden. For more information on Albireo,
please visit www.albireopharma.com.
Media Contacts:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024